Skip to main content

Peer Review reports

From: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

Original Submission
27 Mar 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
6 May 2022 Reviewed Reviewer Report
24 May 2022 Reviewed Reviewer Report
17 Jul 2022 Author responded Author comments - R.K. Ismail
Resubmission - Version 3
17 Jul 2022 Submitted Manuscript version 3
19 Jul 2022 Author responded Author comments - R.K. Ismail
Resubmission - Version 4
19 Jul 2022 Submitted Manuscript version 4
6 Aug 2022 Reviewed Reviewer Report
23 Aug 2022 Reviewed Reviewer Report
19 Sep 2022 Author responded Author comments - R.K. Ismail
Resubmission - Version 5
19 Sep 2022 Submitted Manuscript version 5
4 Oct 2022 Reviewed Reviewer Report
17 Oct 2022 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
19 Oct 2022 Editorially accepted
3 Jan 2023 Article published 10.1186/s12874-022-01760-0

You can find further information about peer review here.

Back to article page